In the published article, there was an error in Figures 3E, 4E as published. The images of Vehicle in Figure 3E and TEOA + GSH in Figure 4E were incorrect. The corrected Figures 3E, 4E and its caption appear below.
FIGURE 3
FIGURE 4
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
TEOA, diffuse large B-cell lymphoma, DNA damage, reactive oxygen species, p38 MAPK
Citation
Yu X, Wang X, Wang X, Zhou Y, Li Y, Wang A, Wang T, An Y, Sun W, Du J, Tong X and Wang Y (2022) Corrigendum: TEOA inhibits proliferation and induces DNA damage of diffuse large B-cell lymphoma cells through activation of the ROS-dependent p38 MAPK signaling pathway. Front. Pharmacol. 13:973989. doi: 10.3389/fphar.2022.973989
Received
20 June 2022
Accepted
01 July 2022
Published
12 August 2022
Volume
13 - 2022
Edited and reviewed by
Xu Zhang, Jiangsu University, China
Updates
Copyright
© 2022 Yu, Wang, Wang, Zhou, Li, Wang, Wang, An, Sun, Du, Tong and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ying Wang, nancywangying@163.com; Jing Du, dujing1@hmc.edu.cn; Xiangmin Tong, tongxiangmin@163.com
†These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.